| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1368-5031.2005.00617.X |
| P698 | PubMed publication ID | 16033615 |
| P2093 | author name string | Haab F | |
| Castro-Diaz D | |||
| P2860 | cites work | Evaluation and treatment of the overactive bladder | Q34778719 |
| P433 | issue | 8 | |
| P304 | page(s) | 931-937 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | International Journal of Clinical Practice | Q15758177 |
| P1476 | title | Persistence with antimuscarinic therapy in patients with overactive bladder | |
| P478 | volume | 59 |
| Q47143545 | An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents. |
| Q35042575 | An overview of the clinical use of antimuscarinics in the treatment of overactive bladder |
| Q86656033 | Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis |
| Q43850341 | Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder |
| Q31013378 | Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model |
| Q35237161 | Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective |
| Q46051446 | Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study |
| Q27000698 | Does fesoterodine have a role in the treatment of poorly managed patients with overactive bladder? |
| Q50908824 | Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder. |
| Q37831263 | Falls risk reduction and treatment of overactive bladder symptoms with antimuscarinic agents: a scoping review |
| Q34982181 | Medication adherence in the management of nocturia: challenges and solutions |
| Q34564708 | Muscarinic receptors in the bladder: from basic research to therapeutics |
| Q47189750 | No Increased Risk of Fracture in Patients Receiving Antimuscarinics for Overactive Bladder Syndrome: A Retrospective Cohort Study. |
| Q83811785 | Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin |
| Q48030253 | Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience |
| Q82574887 | Pharmacotherapy of urinary incontinence |
| Q37116772 | Positive association of female overactive bladder symptoms and estrogen deprivation: A nationwide population-based cohort study in Taiwan |
| Q35545723 | Purinoceptors as therapeutic targets for lower urinary tract dysfunction |
| Q48390526 | Success rates, quality of life, and feasibility of sacral nerve stimulation in elderly patients: 1-year follow-up |
| Q37836943 | The medical treatment of overactive bladder, including current and future treatments. |
| Q35643253 | The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty |
| Q34502903 | Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review |
| Q38543432 | Tolterodine in the Treatment of Male LUTS. |
| Q28308162 | Trospium chloride treatment of overactive bladder |
| Q84402238 | Will the evolution of overactive bladder delivery systems increase patient compliance? |
Search more.